Drug maker Amgen, which recently said that it won’t raise prices again this year, is crediting the Trump administration’s effort to steady the price of drugs.

In a transcript of the company’s earnings call, Amgen Chairman and CEO Robert A. Bradway said, “We appreciate the administration’s engagement on this important issue. As to prices, we made the decision a few months ago not to increase the prices of any of our medicines at mid-year. And we have no plans to change that through the balance of the year.”

The president has pushed companies to lower prices and promised that many would. Amgen is one of the biggest to act since Trump made his promise. Alex Azar, his Health and Human Services Department secretary, recently testified in Congress that companies will announce price freezes after second quarter reports.

[HHS Secretary Alex Azar: New round of drug price hikes a ‘tipping point’]

The move by Amgen, one of the world’s biggest, came after it reported a better-than-expected second quarter profit.

Amgen Executive Vice President of Global Commercial Operations Anthony C. Hooper said, “We have not increased the list prices of any of our medicines since the administration’s drug pricing blueprint was issued, and in May we decided not to execute list price increases that had been planned for July.”